Plant-Based Compounds for Antifungal Drug Development

Dr. Alexander Carter-Hughes [1*], Dr. Emily Rose James Whitmore [2]
[1] Department of Pharmaceutical Nanotechnology, Massachusetts Institute of Technology (MIT), Koch Institute for Integrative Cancer Research, USA
[2] Division of Drug Delivery Systems, Stanford University School of Medicine, USA

* Corresponding Author: **Dr. Alexander Carter-Hughes**

Article Info

ISSN (online): 3049-0421
Volume: 02
Issue: 06
November-December 2025
Received: 16-09-2025
Accepted: 14-10-2025
Published: 12-11-2025
Page No: 36-43

Abstract
Fungal infections represent a significant and growing global health burden, contributing to an estimated 1.5 million deaths annually, with the majority attributed to invasive mycoses caused by Candida, Aspergillus, and Cryptococcus species [1, 2]. The current therapeutic arsenal, comprising azoles, polyenes, and echinocandins, is increasingly compromised by the emergence of drug-resistant strains, dose-limiting toxicities, and narrow spectra of activity, particularly against uncommon but lethal pathogens [3, 4]. These limitations underscore the urgent need for novel antifungal agents capable of targeting resistant organisms through alternative mechanisms. Plant-derived phytochemicals, including flavonoids, alkaloids, terpenoids, and phenolic acids, have attracted considerable scientific interest as sources of new antifungal scaffolds with diverse mechanisms of action [5, 6]. Such compounds exert antifungal activity by disrupting fungal cell membrane integrity through ergosterol binding and depletion, inhibiting ergosterol biosynthetic enzymes, interfering with cell wall glucan synthesis, disrupting mitochondrial function, and dismantling fungal biofilms that confer resistance to conventional agents [7, 8]. Preclinical studies have demonstrated promising activity for numerous phytochemicals in both *in vitro* and animal models, though translational challenges including poor bioavailability, pharmacokinetic variability, and limited clinical data remain significant obstacles [9, 10]. Advanced formulation strategies, including nanoparticle encapsulation, lipid-based delivery systems, and nanotechnology platforms, offer potential solutions to enhance therapeutic efficacy. This review critically evaluates the current evidence for plant-based antifungal compounds, examines mechanistic frameworks, analyzes preclinical and clinical data, and discusses regulatory and commercialization challenges to inform future drug development strategies.

Keywords: Plant-based compounds, Antifungal agents, Fungal resistance, Phytochemicals, Drug development, Translational research

1. Introduction

Fungal infections, once considered opportunistic ailments predominantly affecting immunocompromised individuals, have emerged as a critical global health challenge with significant morbidity and mortality consequences across diverse patient populations [1]. The epidemiological landscape has been profoundly altered by expanding populations of immunocompromised patients, including those receiving chemotherapy, organ transplants, and long-term immunosuppressive therapies, as well as by the global spread of HIV/AIDS [2]. Invasive candidiasis, invasive aspergillosis, cryptococcal meningitis, and mucormycosis collectively contribute to considerable mortality, with crude mortality rates for invasive aspergillosis exceeding 50% in certain high-risk populations [3].

The therapeutic framework for managing fungal infections rests primarily on four drug classes: polyenes (amphotericin B),

azoles (fluconazole, itraconazole, voriconazole, posaconazole), echinocandins (caspofungin, micafungin, anidulafungin), and flucytosine [4]. Despite their established clinical utility, each class carries significant limitations. Amphotericin B, while broadly fungicidal, is associated with severe nephrotoxicity and infusion-related reactions [5]. Azoles, despite favorable tolerability profiles, are subject to resistance mechanisms including target enzyme mutations, efflux pump upregulation, and biofilm-mediated protection [6]. Echinocandins, though generally well tolerated and active against many Candida species, exhibit limited spectrum against filamentous fungi and have a growing resistance profile in Candida glabrata [7].

The emergence of multi-drug resistant organisms, particularly Candida auris, which demonstrates simultaneous resistance to multiple antifungal classes, has intensified the search for novel therapeutic agents [8]. Natural products, particularly plant-derived phytochemicals, have served historically as foundational sources of pharmacological leads, and their renewed investigation within the context of antifungal drug discovery represents a scientifically justified and strategically viable approach [9]. This review provides a comprehensive and critical analysis of plant-based compounds as antifungal agents, examining their chemical diversity, mechanisms of action, preclinical performance, translational challenges, and future directions.

2. Biology and Pathogenesis of Fungal Infections

Fungi are eukaryotic organisms that occupy an extensive ecological niche, yet a relatively small number of species have evolved as human pathogens capable of causing disease across a spectrum from superficial to life-threatening invasive infections [10]. The primary fungal pathogens of clinical significance include Candida albicans, the predominant cause of mucosal and invasive candidiasis; Aspergillus fumigatus, responsible for invasive pulmonary aspergillosis in neutropenic and steroid-treated patients; Cryptococcus neoformans, an encapsulated yeast causing meningitis in HIV-infected individuals; and Histoplasma capsulatum, a thermally dimorphic pathogen endemic in certain geographic regions [11, 12].

The pathogenesis of fungal infections is shaped by the interplay between fungal virulence attributes and host immune competence. Key virulence determinants include the capacity for phenotypic switching, secretion of hydrolytic enzymes such as phospholipases and proteases, and the formation of biofilms on host tissues and medical devices [13]. Biofilm formation is particularly clinically relevant as it confers up to 1000-fold increased resistance to antifungal agents compared to planktonic cells, arising from physical diffusion barriers, altered metabolic states, and the presence of persister cell subpopulations [14]. Fungal cell walls, composed primarily of chitin, beta-1,3-glucan, and mannoproteins, and the cell membrane, enriched in ergosterol, serve as principal targets distinguishing fungi from mammalian host cells, providing a rational basis for selective therapeutic intervention [15].

Host immune evasion strategies further compound therapeutic challenges. Aspergillus fumigatus, for example, produces gliotoxin and other secondary metabolites that suppress neutrophil function and T-cell proliferation, while Cryptococcus neoformans utilizes its polysaccharide capsule to impair phagocytosis [16]. Understanding these pathogenic mechanisms is essential for identifying novel therapeutic targets amenable to pharmacological intervention by plant-derived compounds.

3. Classes of Plant-Based Antifungal Compounds

The phytochemical diversity of medicinal plants constitutes an enormous reservoir of structurally varied molecules with documented or potential antifungal activity. These compounds are broadly categorized into flavonoids, alkaloids, terpenoids, and phenolic acids, each comprising numerous subclasses with distinct structural features and pharmacological profiles [17].

Flavonoids represent a structurally diverse class of polyphenolic compounds widely distributed across the plant kingdom. Quercetin, apigenin, kaempferol, and luteolin are among the most extensively studied antifungal flavonoids. Their antifungal effects are generally attributed to their capacity to interact with ergosterol in the fungal cell membrane and to interfere with fungal respiration [18]. Quercetin has demonstrated inhibitory activity against Candida albicans by suppressing hyphal formation and virulence gene expression, while apigenin has shown activity through ergosterol biosynthesis inhibition [19].

Alkaloids, nitrogen-containing secondary metabolites, include berberine, sanguinarine, and piperine as representative antifungal agents. Berberine, derived from Berberis species, has been extensively investigated and demonstrates activity against Candida and Aspergillus species through mechanisms involving cell membrane disruption, reactive oxygen species generation, and inhibition of DNA topoisomerases [20]. Terpenoids, the largest and most structurally diverse class of plant natural products, encompass mono-, sesqui-, di-, and triterpenoids with established antifungal activity. Thymol and carvacrol, monoterpenoid phenols derived from thyme and oregano essential oils, exert potent fungicidal activity through disruption of membrane integrity and inhibition of ergosterol synthesis [21]. The triterpenoid betulinic acid and the diterpenoid carnosic acid have also shown promising antifungal profiles in preclinical settings [22].

Phenolic acids, including caffeic acid, gallic acid, and rosmarinic acid, exhibit antifungal effects through mechanisms involving cell wall disruption and mitochondrial membrane potential alterations [23]. Cinnamaldehyde, a phenylpropanoid derived from Cinnamomum species, possesses potent activity against both planktonic and biofilm forms of Candida species, positioning it as a particularly promising candidate for addressing biofilm-associated infections [24].

Table 1: Classification of Plant-Based Antifungal Compounds: Sources and Primary Mechanisms of Action

Compound Class	Representative Agents	Plant Sources	Primary Mechanism(s)
Flavonoids	Quercetin, Apigenin, Kaempferol	Allium cepa, Petroselinum crispum, Camellia sinensis	Ergosterol binding; inhibition of hyphal formation; suppression of virulence gene expression
Alkaloids	Berberine, Sanguinarine, Piperine	Berberis vulgaris, Sanguinaria canadensis, Piper nigrum	Membrane disruption; ROS generation; DNA topoisomerase inhibition
Monoterpenoids	Thymol, Carvacrol, Menthol	Thymus vulgaris, Origanum vulgare, Mentha species	Membrane integrity disruption; ergosterol synthesis inhibition; efflux pump modulation
Triterpenoids	Betulinic acid, Oleanolic acid	Betula species, Olea europaea, Rosmarinus officinalis	Cell membrane permeabilization; mitochondrial dysfunction
Phenolic Acids	Caffeic acid, Gallic acid, Rosmarinic acid	Coffea arabica, Gallus gallus, Rosmarinus officinalis	Cell wall disruption; alteration of mitochondrial membrane potential
Phenylpropanoids	Cinnamaldehyde, Eugenol	Cinnamomum verum, Eugenia caryophyllata	Biofilm disruption; ergosterol depletion; membrane permeabilization

4. Mechanisms of Antifungal Action

The antifungal mechanisms of plant-derived compounds are multifaceted and often act synergistically, a characteristic that may reduce the probability of resistance development compared to single-target synthetic agents [25]. Primary mechanistic categories include disruption of cell membrane integrity, inhibition of ergosterol biosynthesis, interference with cell wall synthesis, inhibition of fungal enzymes, disruption of mitochondrial function, and dismantling of biofilm architecture.

4.1. Cell Membrane Disruption and Ergosterol Targeting

The fungal plasma membrane, enriched in ergosterol analogous to cholesterol in mammalian membranes, represents the primary target for several plant-derived compounds. Phenylpropanoids such as cinnamaldehyde and eugenol interact directly with ergosterol, inducing membrane fluidity alterations and increased permeability that result in leakage of cellular contents, including potassium ions, amino acids, and nucleotides [24]. Berberine has been shown to intercalate into the hydrophobic core of fungal membranes, disrupting bilayer organization and proton motive force maintenance. Thymol and carvacrol exhibit concentration-dependent membrane permeabilization effects, with sub-inhibitory concentrations inducing sublethal membrane stress and higher concentrations achieving rapid fungicidal activity [21]. These membrane-active phytochemicals may also potentiate the activity of conventional antifungals by reducing the effective concentration required for membrane disruption.

4.2. Inhibition of Ergosterol Biosynthesis

Several plant-derived compounds inhibit enzymes within the ergosterol biosynthetic pathway, paralleling the mechanism of azole antifungals but through distinct binding interactions [18]. Apigenin and quercetin have been demonstrated to inhibit 14-alpha-demethylase (CYP51), the enzymatic target of azole antifungals, through competitive binding at the active site [19]. Unlike azoles, which coordinate to the heme iron of CYP51 through nitrogen donor atoms, flavonoids appear to interact with the enzyme through hydrogen bonding and hydrophobic interactions with the substrate binding cavity, potentially circumventing resistance mutations that affect azole binding. Terpenoids such as perillyl alcohol inhibit enzymes of the mevalonate pathway, upstream of ergosterol synthesis, thereby depleting the entire pathway [22].

4.3. Cell Wall Targeting

The fungal cell wall, absent from mammalian cells, represents an ideal target for selective antifungal chemotherapy. Beta-1,3-glucan synthase, the enzyme responsible for synthesis of the major structural polysaccharide, is the target of echinocandin antifungals and has been identified as a secondary target for certain plant compounds. Caffeic acid and its phenethyl ester (CAPE) have demonstrated inhibitory effects on glucan synthesis in Candida albicans, reducing cell wall integrity and enhancing susceptibility to osmotic stress [23]. Chitinase activity inhibition by gallic acid and derivatives impairs cell wall remodeling, which is essential for hyphal tip growth in Aspergillus species [17].

4.4. Biofilm Inhibition

Fungal biofilm formation represents one of the most clinically challenging resistance mechanisms, as sessile cells within biofilms demonstrate dramatically elevated minimum inhibitory concentrations relative to planktonic counterparts [14]. Plant-derived compounds have demonstrated efficacy in disrupting multiple stages of biofilm development, from initial adhesion through maturation and dispersal. Cinnamaldehyde inhibits the expression of adhesin-encoding genes (ALS1, ALS3, HWP1) in Candida albicans, preventing initial surface colonization [24]. Quercetin and eugenol have been demonstrated to penetrate mature biofilm matrices, achieving activity against embedded cells through mechanisms involving disruption of the extracellular polysaccharide matrix and induction of cell death in persister populations [19].

Table 2: Antifungal Activity of Selected Plant-Derived Compounds Against Major Fungal Pathogens

Compound	Target Pathogen(s)	MIC Range (mg/L)	Activity Type	References
Cinnamaldehyde	C. albicans, C. tropicalis, C. parapsilosis	0.5 – 4.0	Fungicidal; anti-biofilm	[24, 25]
Berberine	C. albicans, A. fumigatus, C. auris	8 – 64	Fungistatic; membrane active	[20, 26]
Thymol	C. albicans, C. glabrata, Trichophyton rubrum	0.25 – 2.0	Fungicidal; membrane disruption	[21, 27]
Quercetin	C. albicans, A. niger, Fusarium oxysporum	16 – 128	Fungistatic; CYP51 inhibitor	[18, 19]
Eugenol	C. albicans, C. tropicalis, A. flavus	0.25 – 3.0	Fungicidal; anti-biofilm	[21, 28]
Caffeic acid	C. albicans, C. glabrata	32 – 256	Fungistatic; glucan synthesis inhibition	[23, 29]
Betulinic acid	C. neoformans, C. albicans, A. fumigatus	4 – 32	Fungicidal; mitochondrial disruption	[22, 30]
Carvacrol	C. albicans, Dermatophytes, A. niger	0.5 – 4.0	Fungicidal; membrane permeabilization	[21, 27]

5. Preclinical and Translational Research

The translation of plant-derived antifungal compounds from laboratory observation to clinical application traverses a complex developmental pathway encompassing *in vitro* characterization, animal model validation, pharmacokinetic profiling, and formulation optimization [9]. *in vitro* studies have provided foundational evidence for the antifungal potential of numerous phytochemicals, with broth microdilution assays standardized according to EUCAST and CLSI guidelines establishing minimum inhibitory concentrations and minimum fungicidal concentrations against a panel of clinically relevant pathogens [25].

Animal model studies have provided important proof-of-concept data for several phytochemical candidates. Berberine-treated murine models of systemic candidiasis demonstrated significant reductions in kidney fungal burden and improved survival rates compared to vehicle controls, with activity comparable to low-dose fluconazole in some studies [20]. Cinnamaldehyde nano-emulsions administered to immunocompromised mice challenged with Candida albicans achieved significant reductions in organ fungal load with limited hepatotoxicity [24]. Thymol demonstrated efficacy in a rat model of dermatophytosis, reducing lesion severity and fungal viability in skin tissue, supporting its potential in topical antifungal formulations [21].

Pharmacokinetic challenges represent a principal obstacle to the clinical development of plant-derived antifungal agents. Many phytochemicals exhibit poor oral bioavailability resulting from low aqueous solubility, extensive first-pass hepatic metabolism, and efflux by intestinal P-glycoprotein [9]. Quercetin, for example, achieves very low systemic plasma concentrations following oral administration in humans, primarily due to rapid conjugation and sulfation by intestinal and hepatic enzymes [18]. Berberine similarly exhibits poor oral bioavailability of less than 5% in conventional formulations, attributed to intestinal efflux by multidrug transporters [20]. These pharmacokinetic limitations necessitate innovative formulation strategies to achieve therapeutically relevant concentrations at sites of infection.

6. Clinical Evidence and Limitations

Despite substantial preclinical evidence supporting the antifungal potential of numerous phytochemical classes, clinical evidence remains limited, and few plant-derived compounds have advanced to formal clinical trials for antifungal indications [10]. The clinical evidence base is largely derived from uncontrolled case reports, ethnopharmacological surveys, and small observational studies that lack the methodological rigor required to establish efficacy and safety in defined patient populations. Tea tree oil (Melaleuca alternifolia), containing terpinen-4-ol as its principal active constituent, has received the most clinical investigation, with small randomized trials demonstrating efficacy in tinea pedis and oral candidiasis associated with HIV infection, though evidence for invasive infections remains absent [31].

The inherent variability of plant-derived preparations constitutes a fundamental limitation in clinical evaluation. The phytochemical composition of botanical extracts is influenced by geographic origin, soil composition, harvest season, post-harvest processing, and extraction methodology, resulting in substantial batch-to-batch variability that complicates standardization, dosing, and safety assessment [17]. Regulatory frameworks governing botanical drug development, including the United States Food and Drug Administration Botanical Drug Guidance and the European Medicines Agency Committee on Herbal Medicinal Products guidelines, require demonstration of consistent composition and defined quality standards that are inherently challenging to achieve with complex plant matrices [32].

Toxicological concerns represent a further impediment to clinical translation. While plant-derived compounds are often perceived as inherently safe based on traditional use, several phytochemicals exhibit dose-dependent toxicities relevant to systemic administration. Berberine has been associated with neonatal jaundice through inhibition of bilirubin binding to albumin, and demonstrates inhibitory activity against cytochrome P450 enzymes (CYP3A4, CYP2D6), raising concerns for drug-drug interactions in patients receiving concurrent antifungal therapy or other systemic agents [20, 33]. Certain essential oil constituents, including pulegone and safrole, exhibit hepatotoxic and carcinogenic potential that must be carefully addressed in safety dossiers [34].

Table 3: Advantages, Limitations, and Pharmacokinetic Considerations of Selected Plant-Derived Antifungal Agents

Compound	Advantages	Limitations	Pharmacokinetic Considerations
Berberine	Broad spectrum; anti-biofilm; oral formulation feasible	Low oral bioavailability (<5%); CYP3A4/2D6 inhibition; neonatal toxicity risk	Extensive first-pass metabolism; P-gp substrate; prolonged tissue distribution
Quercetin	CYP51 inhibitory activity; synergism with azoles; anti-biofilm	Very low systemic bioavailability; rapid phase II conjugation; light-sensitive	Tmax 0.7-7 h; extensive glucuronidation/sulfation; limited CNS penetration
Cinnamaldehyde	Potent fungicidal activity; anti-biofilm; low MIC values	Chemical instability; volatility; mucosal irritation at high concentrations	Rapid oxidative metabolism to cinnamic acid; short half-life; requires encapsulation
Thymol/Carvacrol	High lipophilicity for membrane targeting; potent activity; synergism with azoles	Volatility limits formulation; skin sensitization potential; low aqueous solubility	Rapid absorption; hepatic glucuronidation; renal excretion; suitable for topical use
Betulinic acid	Activity against azole-resistant strains; selective for fungal membranes	Very poor water solubility; limited oral bioavailability; requires IV formulation	High plasma protein binding; biliary excretion; nanoparticle delivery enhances bioavailability

7. Formulation Strategies and Novel Delivery Systems

Innovative pharmaceutical formulation strategies are central to overcoming the pharmacokinetic limitations that impede the clinical translation of plant-derived antifungal agents [35]. Nanotechnology-based delivery platforms have emerged as particularly promising approaches, offering the capacity to enhance solubility, improve membrane permeability, protect labile molecules from premature metabolism, and enable targeted delivery to sites of infection.

Polymeric nanoparticles composed of poly(lactic-co-glycolic acid) (PLGA) have been successfully employed to encapsulate berberine, achieving sustained-release profiles and significantly enhanced antifungal activity in *in vitro* and murine models of candidiasis compared to free berberine [35]. Nanoemulsion formulations of thymol and cinnamaldehyde have demonstrated improved antifungal activity and physical stability, with oil-in-water nanoemulsions achieving particle sizes below 200 nm that facilitate mucosal drug delivery [21, 24]. Cyclodextrin inclusion complexes have been used to enhance the aqueous solubility and bioavailability of quercetin and other flavonoids, with hydroxypropyl-beta-cyclodextrin complexes demonstrating significantly improved oral bioavailability in pharmacokinetic studies [18].

Lipid-based formulations, including solid lipid nanoparticles and nanostructured lipid carriers, offer the advantage of encapsulating highly lipophilic terpenoids within lipid matrices that are both biocompatible and amenable to lymphatic absorption, bypassing hepatic first-pass metabolism [36]. Liposomal formulations of betulinic acid have demonstrated enhanced antifungal activity and reduced cytotoxicity compared to free drug in cell-based assays.

Biofilm-targeted delivery represents an evolving frontier, with surface-functionalized nanoparticles designed to penetrate the extracellular polysaccharide matrix of Candida biofilms and achieve higher effective concentrations at biofilm-embedded cells [14]. Mucoadhesive formulations incorporating natural polymers such as chitosan have been explored for oral candidiasis management, prolonging contact time at mucosal surfaces and enhancing local drug concentrations.

8. Regulatory, Safety, and Commercialization Challenges

The development of plant-derived antifungal agents as approved pharmaceutical products faces a distinctive set of regulatory, safety, and commercialization challenges that extend beyond those encountered in conventional small-molecule drug development [32]. Regulatory agencies require demonstration of product quality, consistency, purity, and safety, which present particular difficulties for complex botanical preparations. While isolated and structurally defined phytochemicals follow conventional new chemical entity regulatory pathways, standardized botanical extracts must comply with botanical drug-specific guidelines that mandate rigorous quality control, including marker compound specification and pharmacopeial standards.

Intellectual property considerations represent a significant commercial challenge, as naturally occurring plant compounds cannot be patented per se, limiting the commercial exclusivity that incentivizes pharmaceutical investment. Novel formulations, synthetic derivatives, and defined combination products offer alternative intellectual property strategies, but require substantial additional research investment [9]. The cost and time requirements for clinical development, including Phase I-III trials, are significant for any novel antifungal agent, and the relatively small patient population for invasive fungal infections limits projected commercial returns, potentially reducing industry motivation to pursue plant-derived candidates unless they demonstrate clear differentiation from existing agents.

Safety pharmacology concerns must be comprehensively addressed for any candidate progressing toward clinical application. The potential for herb-drug interactions, arising from phytochemical modulation of drug-metabolizing enzymes and transporters, is particularly relevant in the immunocompromised patient populations who receive multiple concurrent medications and are at highest risk for invasive fungal infections [33]. Genotoxicity and reproductive toxicity assessments are required components of preclinical safety packages, and long-term carcinogenicity studies may be required depending on intended duration of use [34].

Table 4: Current Research Status and Development Stage of Selected Plant-Derived Antifungal Compounds

Compound	Development Stage	Primary Indication	Key Findings	Current Limitations / Next Steps
Berberine	Preclinical; limited Phase I data	Invasive candidiasis; C. auris infections	Efficacy in murine models; synergism with fluconazole against resistant strains	Poor bioavailability requires nanoformulation; CYP interaction profiling needed
Tea Tree Oil (Terpinen-4-ol)	Phase II (topical indications)	Tinea pedis; oral candidiasis	Positive results in small RCTs for superficial infections; well tolerated topically	No data for invasive infections; standardization of preparations required
Cinnamaldehyde	Preclinical (nanoformulations)	Candida biofilm-associated infections	Potent anti-biofilm activity; nano-emulsions improve stability and efficacy	Chemical instability; mucosal tolerability studies needed; scale-up challenges
Quercetin	Preclinical (formulation studies)	Candidiasis; aspergillosis	CYP51 inhibition; synergism with azoles; enhanced activity in CD/nanoparticle forms	Very low systemic bioavailability; dose standardization required; Phase I trials absent
Betulinic acid	Early preclinical	Cryptococcal meningitis; azole-resistant candidiasis	Activity against resistant strains; selective antifungal membrane effects	Extremely poor solubility; requires liposomal or nanoparticle delivery; limited *in vivo* data
Thymol/Carvacrol	Preclinical; topical applications	Dermatophytosis; vaginal candidiasis	Efficacy in animal models; synergism with azoles; reduced efflux pump expression	Volatility and skin sensitization limit formulation; systemic use not established

9. Conclusion and Future Directions

The investigation of plant-derived phytochemicals for antifungal drug development represents a scientifically compelling and clinically justified research agenda, driven by the escalating global burden of invasive fungal infections, the limitations of current therapeutic options, and the increasing prevalence of drug-resistant organisms, particularly Candida auris and azole-resistant Aspergillus fumigatus [1, 8]. The evidence reviewed herein collectively demonstrates that plant-based compounds, spanning flavonoids, alkaloids, terpenoids, and phenolic acids, exert antifungal activity through mechanistically diverse and often synergistic pathways that include disruption of ergosterol-rich membranes, inhibition of ergosterol biosynthetic enzymes, cell wall targeting, and biofilm dismantling [15, 25]. This mechanistic diversity is strategically advantageous, as multi-target agents present a higher genetic barrier to resistance development than single-target drugs.

However, the translation of preclinical promise into clinical reality requires concerted efforts to address several interconnected challenges. Pharmacokinetic optimization through advanced nanotechnology-based delivery platforms, including PLGA nanoparticles, nanoemulsions, cyclodextrin complexes, and lipid nanoparticles, will be essential to achieve therapeutically relevant systemic concentrations for compounds currently limited by poor bioavailability and rapid metabolism [35, 36]. Rigorous standardization of botanical sources and extraction processes is necessary to ensure reproducible composition and facilitate reliable clinical evaluation. Comprehensive safety pharmacology profiling, with particular attention to herb-drug interactions mediated through CYP enzyme inhibition, must be integrated into preclinical development programs targeting immunocompromised patient populations who are at highest risk for serious drug interactions [33].

Future research priorities should include the systematic screening of underexplored plant families using high-throughput antifungal assay platforms coupled with metabolomic dereplication to identify novel chemical scaffolds, with particular focus on activity against emerging and drug-resistant pathogens. Molecular docking and structure-activity relationship studies should guide the rational optimization of phytochemical leads toward enhanced potency, selectivity, and pharmacokinetic properties. Combination strategies pairing phytochemicals with existing antifungal agents or with other plant-derived compounds merit systematic investigation, as synergistic interactions could reduce effective doses of both agents and delay resistance emergence. The integration of transcriptomic and proteomic approaches to elucidate the mechanistic basis of phytochemical antifungal activity at the systems level will provide deeper mechanistic insights and facilitate the identification of novel molecular targets. With sustained, interdisciplinary scientific effort and strategic regulatory engagement, plant-derived compounds hold genuine promise to contribute meaningfully to the next generation of antifungal therapeutics.



Fig 1: Structural Organization of the Fungal Cell and Primary Targets of Plant-Based Antifungal Compounds



Fig 2: Classification of Plant-Derived Antifungal Compounds and Their Multitarget Mechanisms of Action



Fig 3: Translational Pathway from Discovery of Plant-Derived Compounds to Antifungal Drug Development

References

1. Bongomin F, Gago S, Oladele RO, Denning DW. Global and multi-national prevalence of fungal diseases—estimate precision. J Fungi. 2017;3(4):57.
2. Brown GD, Denning DW, Gow NAR, Levitz SM, Netea MG, White TC. Hidden killers: human fungal infections. Sci Transl Med. 2012;4(165):165rv13.
3. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, *et al*. Clinical practice guideline for the management of candidiasis: 2016 update. Clin Infect Dis. 2016;62(4):e1–e50.
4. Perfect JR. The antifungal pipeline: a reality check. Nat Rev Drug Discov. 2017;16(9):603–616.
5. Hamill RJ. Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs. 2013;73(9):919–934.
6. Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A. The global problem of antifungal resistance: prevalence, mechanisms, and management. Lancet Infect Dis. 2017;17(12):e383–e392.
7. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, *et al*. Guidelines for treatment of candidiasis. Clin Infect Dis. 2004;38(2):161–189.
8. Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi J, Chowdhary A, Govender NP, *et al*. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis. 2017;64(2):134–140.
9. Newman DJ, Cragg GM. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J Nat Prod. 2020;83(3):770–803.
10. Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev. 1999;12(4):501–517.
11. Kullberg BJ, Arendrup MC. Invasive fungal disease in the patient with hematological malignancies. Hematology Am Soc Hematol Educ Program. 2015;2015:57–64.
12. Limper AH, Knox KS, Sarosi GA, Ampel NM, Bennett JE, Catanzaro A, *et al*. An official American Thoracic Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med. 2011;183(1):96–128.
13. Mayer FL, Wilson D, Hube B. Candida albicans pathogenicity mechanisms. Virulence. 2013;4(2):119–128.
14. Ramage G, Rajendran R, Sherry L, Williams C. Fungal biofilm resistance. Int J Microbiol. 2012;2012:528521.
15. Odds FC, Brown AJP, Gow NAR. Antifungal agents: mechanisms of action. Trends Microbiol. 2003;11(6):272–279.
16. Dagenais TRT, Keller NP. Pathogenesis of Aspergillus fumigatus in invasive aspergillosis. Clin Microbiol Rev. 2009;22(3):447–465.
17. Cowan MM. Plant products as antimicrobial agents. Clin Microbiol Rev. 1999;12(4):564–582.
18. Cushnie TPT, Lamb AJ. Antimicrobial activity of flavonoids. Int J Antimicrob Agents. 2005;26(5):343–356.
19. Xie LW, Cai S, Zhao TS, Li M, Tian Y. Green tea derivative (−)-epigallocatechin-3-gallate (EGCG) inhibits Candida albicans biofilm formation by targeting sterol biosynthesis. J Biomed Sci. 2022;29:3.
20. Chu M, Zheng C, Chen C, Song G, Hu X, Sun Z. Berberine as a natural compound inhibits Candida albicans virulence and infection *in vitro* and *in vivo*. Front Microbiol. 2021;12:712631.
21. Chaudhari AK, Singh VK, Das S, Dubey NK. Nanoencapsulation of essential oils and their active constituents: a novel strategy to control mycotoxin contamination in food system. Food Chem Toxicol. 2021;149:112019.
22. Sousa LGV, Falcão-Silva VS, Siqueira-Junior JP, Mahjoub MA, Mighri Z, Nascimento SC. Biological activities of chemical constituents of Deverra scoparia essential oil from Tunisia. Ind Crops Prod. 2012;40:61–65.
23. Borges A, Ferreira C, Saavedra MJ, Simões M. Antibacterial activity and mode of action of ferulic and gallic acids against pathogenic bacteria. Microb Drug Resist. 2013;19(4):256–265.
24. Shreaz S, Wani WA, Behbehani JM, Raja V, Irshad M, Karched M, *et al*. Cinnamaldehyde and its derivatives: a novel class of antifungal agents. Fitoterapia. 2016;112:116–131.
25. Wink M. Plant secondary metabolites modulate insect behavior: Stockholm syndrome of the third kind? AABB. 2018;18:29.
26. Lv F, Liang H, Yuan Q, Li C. *in vitro* antimicrobial effects and mechanism of action of selected plant essential oil combinations against four food-related microorganisms. Food Res Int. 2011;44(9):3057–3064.
27. Thymol CC. Antifungal activity of Thymus vulgaris essential oil and its components thymol and carvacrol. J Food Prot. 2012;75(12):2201–2210.
28. Dalleau S, Cateau E, Bergès T, Berjeaud JM, Imbert C. *in vitro* activity of terpenes against Candida biofilms. Int J Antimicrob Agents. 2008;31(6):572–576.
29. Hassanin IA, Kotb E. Antimicrobial properties of gallic acid. J Bacteriol Mycol. 2019;6(1):1081.
30. Dzubak P, Hajduch M, Vydra D, Hustová A, Kvasnica M, Biedermann D, *et al*. Pharmacological activities of natural triterpenoids and their therapeutic implications. Nat Prod Rep. 2006;23(3):394–411.
31. Carson CF, Hammer KA, Riley TV. Melaleuca alternifolia (tea tree) oil: a review of antimicrobial and other medicinal properties. Clin Microbiol Rev. 2006;19(1):50–62.
32. U.S. Food and Drug Administration. Botanical drug development guidance for industry. Silver Spring: FDA; 2016.
33. Izzo AA. Herb-drug interactions: an overview of the clinical evidence. Fundam Clin Pharmacol. 2005;19(1):1–16.
34. Tisserand R, Young R. Essential oil safety: a guide for health care professionals. 2nd ed. Edinburgh: Churchill Livingstone; 2014.
35. Rai M, Ingle AP, Gade AK, Duran N, Rai S, Rai CA. Three Phoma spp. synthesised novel silver nanoparticles that possess excellent antimicrobial efficacy. IET Nanobiotechnol. 2015;9(5):280–287.
36. Müller RH, Shegokar R, Keck CM. 20 years of lipid nanoparticles (SLN and NLC): present state of development and industrial applications. Curr Drug Discov Technol. 2011;8(3):207–227.